Billy Kelleher (Cork North Central, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

To ask the Minister for Health when cancer patients will expect to be able to receive ipilimumab; the reasons for the further delay in its provision; and if he will make a statement on the matter. [37089/12]

James Reilly (Dublin North, Fine Gael)
Link to this: Individually | In context | Oireachtas source

From 3 May, 2012 Ipilimumab has been available to all eligible patients with progressive melanoma treated in public hospitals. There have been no reported delays in relation to its provision.

The Director of the HSE's National Cancer Control Programme (NCCP) is aware that some private insurers were in ongoing negotiations with the manufacturers to agree reimbursement of Ipilimumab for patients treated in private hospitals. As the NCCP does not have responsibility for patients treated in private hospitals any query in relation to the provision of this drug, in the private hospital setting, should be addressed directly with the manufacturers.

Billy Kelleher (Cork North Central, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

To ask the Minister for Health when cancer patients may expect to be able to receive Gilenya; the reasons for the further delay in its provision; and if he will make a statement on the matter. [37090/12]

Róisín Shortall (Dublin North West, Labour)
Link to this: Individually | In context | Oireachtas source

Gilenya, which is used for the treament of Multiple Sclerosis, has been reimbursed on the High Tech Scheme since 1 July 2012. There is no restriction on the reimbursement of High Tech prescriptions for Gilenya which are written by Neurologists.